Your browser doesn't support javascript.
loading
Early tumor shrinkage indicates a favorable response to bevacizumab-based first-line chemotherapy for metastatic colorectal cancer.
Ito, Mamoru; Kusaba, Hitoshi; Mukaide, Satomi; Kishimoto, Junji; Shimokawa, Hozumi; Tamura, Shingo; Makiyama, Akitaka; Hirano, Gen; Oda, Hisanobu; Shirakawa, Tsuyoshi; Komoda, Masato; Uchino, Keita; Tanaka, Risa; Mitsugi, Kenji; Esaki, Taito; Arita, Shuji; Ariyama, Hiroshi; Akashi, Koichi; Baba, Eishi.
Afiliación
  • Ito M; aDepartment of Hematology and Oncology bCenter for Clinical and Translational Research cDepartment of Research and Development of Next Generation Medicine, Faculty of Medical Science, Kyushu University Hospital dDepartment of Medical Oncology, National Hospital Organization, Kyushu Medical Center eDepartment of Hematology and Oncology, Japan Community Health Care Organization Kyushu Hospital fDepartment of Medical Oncology, Saiseikai Fukuoka General Hospital gDepartment of Medical Oncology, Fuku
Anticancer Drugs ; 28(10): 1166-1173, 2017 11.
Article en En | MEDLINE | ID: mdl-28906258
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Bevacizumab / Antineoplásicos Inmunológicos Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Revista: Anticancer Drugs Asunto de la revista: ANTINEOPLASICOS Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Colorrectales / Bevacizumab / Antineoplásicos Inmunológicos Tipo de estudio: Observational_studies / Prognostic_studies Idioma: En Revista: Anticancer Drugs Asunto de la revista: ANTINEOPLASICOS Año: 2017 Tipo del documento: Article